Ex-Stryker exec dodges jail in insider trading scheme
April 17, 2014 by Brad Perriello
Cardiac Dimensions Inc.
Omada Health gains $23M for digital prevention programs | Medtech funding stories for the week of Apr. 14, 2014
Cardiac Dimensions closes $20M equity round
Cardiac Dimensions said it raised $20 million from a syndicate of international investors for its Carillon mitral valve implant.
M.H. Carnegie & Co. and Lumira Capital led the round for Kirkland, Wash.-based Cardiac Dimensions, according to a press release. Investors in Australia, the U.S. and Canada also participated, the company said.
InVivo taps spine expert as science chief | Personnel Moves
InVivo Therapeutics Holdings Corp. (OTC:NVIV) appointed spinal cord injury expert Dr. Edward Wirth as its new chief scientist.
InVivo brings Wirth to the team as its waiting for a green light by the FDA to begin human trials of its biodegradable scaffold for treating spinal cord injury.
The scaffold is designed to protect and support spinal tissue and prevent secondary injury, including inflammation and glial scarring, following traumatic spinal cord injury.
AtriCure aims for FDA approval with “hybrid” atrial fibrillation trial
The launch of a pivotal clinical trial next year for a “hybrid” procedure to treat atrial fibrillation patients will be an “inflection point” for cardiac surgical device maker AtriCure Inc.’s (NSDQ:ATRC) U.S. business, the company’s CEO said.
The pivotal clinical trial, which could lead to regulatory approval of the hybrid procedure to treat atrial fibrillation and is called DEEP AF, will involve expanding studies from six research centers to 35, CEO David Drachman said.
